Epidrugs in Amyotrophic Lateral Sclerosis/Frontotemporal Dementia: Contextualizing a Role for Histone Kinase Inhibition in Neurodegenerative Disease

Samantha N Cobos; Mariana P Torrente

doi:10.1021/acsptsci.1c00265

Epidrugs in Amyotrophic Lateral Sclerosis/Frontotemporal Dementia: Contextualizing a Role for Histone Kinase Inhibition in Neurodegenerative Disease

ACS Pharmacol Transl Sci. 2022 Jan 21;5(2):134-137. doi: 10.1021/acsptsci.1c00265. eCollection 2022 Feb 11.

Authors

Samantha N Cobos^{1

2}, Mariana P Torrente^{1

2

3

4}

Affiliations

¹ Chemistry Department of Brooklyn College, Brooklyn, New York 11210, United States.
² Ph.D. Program in Chemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States.
³ Ph.D. Program in Biochemistry, The Graduate Center of the City University of New York, New York, New York 10016, United States.
⁴ Ph.D. Program in Biology, The Graduate Center of the City University of New York, New York, New York 10016, United States.

Abstract

Breakthroughs in understanding the epigenetic mechanisms involved in neurodegenerative disease have highlighted "epidrugs" as a potential avenue for therapeutic development. Here, we expand on the future of epidrugs against neurodegeneration and discuss promising novel targets underexploited thus far: histone kinases.